Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human alpha-1 antitrypsin (plant-derived)
- Development stage
- Preclinical
- Lead developer
- Wuhan Healthgen Biotechnology
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Recombinant human alpha-1 antitrypsin (plant-derived) is a recombinant protein produced in rice seeds using Heyuan Biotechnology's proprietary OryzHiExp platform. It is designed as a replacement therapy for individuals with alpha-1 antitrypsin deficiency (AATD), a genetic condition characterized by low levels of the protective protein alpha-1 antitrypsin (A1AT). The drug functions as a serine protease inhibitor, specifically targeting and neutralizing neutrophil elastase to prevent the proteolytic degradation of lung tissue, which otherwise leads to emphysema. As a plant-derived product, it aims to provide a scalable, cost-effective, and pathogen-free alternative to traditional plasma-derived A1AT therapies.
- Other names
- 注射用重组人α1-抗胰蛋白酶（植物源）Recombinant Human Alpha-1 Antitrypsin Injection (plant-derived)Recombinant Human A1AT InjectionRice-derived recombinant human alpha-1 antitrypsin
02
Targets
ElastasePRSS1 (Trypsin family)ELANE (Human Neutrophil Elastase)
Beyond the preview
Go deeper on recombinant human alpha-1 antitrypsin (plant-derived).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human alpha-1 antitrypsin (plant-derived).